ConductScience.org, home

Paper37235366

Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Corasaniti MT and 7 others. Toxins (Basel), 2023. Cited by 19 papers, by iCite.

Cite this record

ConductScience Library. Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Papers, record 37235366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37235366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
PubMed
Journal
Toxins (Basel)
PubMed
Year
2023
PubMed
Publication types
Meta-Analysis, Systematic Review, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
19
iCite
Relative citation ratio, by iCite
3.57
iCite
Revised in PubMed
2025-06-26
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Corasaniti MTMaria Tizianahttps://orcid.org/0000-0001-6472-0697
2Bagetta GGiacintohttps://orcid.org/0000-0001-8540-6218
3Nicotera PPierluigi
4Tarsitano AAssunta
5Tonin PPaolohttps://orcid.org/0000-0002-4867-1378
6Sandrini GGiorgio
7Lawrence GWGary Whttps://orcid.org/0000-0002-5206-7763
8Scuteri DDamianahttps://orcid.org/0000-0001-5846-7058

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Botulinum Toxins, Type AMajor topic
Migraine DisordersMajor topic
Humans
Randomized Controlled Trials as Topic
Headache

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT07040813The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs MonotherapyBackground

Source ClinicalTrials.gov

Download CSV of trials

References129

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134006218Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.J Headache Pain2021https://conductscience.org/library/papers/34006218PubMed
227395386Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?Neurol Sci2016https://conductscience.org/library/papers/27395386PubMed
330879893Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol2019https://conductscience.org/library/papers/30879893PubMed
435410119The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates.J Headache Pain2022https://conductscience.org/library/papers/35410119PubMed
516772757Botulinum toxin type A in prophylactic treatment of migraine.Am J Ther2006https://conductscience.org/library/papers/16772757PubMed
631112399Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.Cephalalgia2019https://conductscience.org/library/papers/31112399PubMed
721956721OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.Neurology2011https://conductscience.org/library/papers/21956721PubMed
829306360The need for better access to pain treatment: learning from drug consumption trends in the USA.Funct Neurol2017https://conductscience.org/library/papers/29306360PubMed
926017508Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.Neurol Sci2015https://conductscience.org/library/papers/26017508PubMed
1020647171OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.Cephalalgia2010https://conductscience.org/library/papers/20647171PubMed
1112111919Quantifying heterogeneity in a meta-analysis.Stat Med2002https://conductscience.org/library/papers/12111919PubMed
1228529184The GRADE Working Group clarifies the construct of certainty of evidence.J Clin Epidemiol2017https://conductscience.org/library/papers/28529184PubMed
1324107267OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.Acta Neurol Scand2014https://conductscience.org/library/papers/24107267PubMed
1431559634FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.Headache2019https://conductscience.org/library/papers/31559634PubMed
1517547312Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.Aviat Space Environ Med2007https://conductscience.org/library/papers/17547312PubMed
1614687015Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study.Cephalalgia2004https://conductscience.org/library/papers/14687015PubMed
1729939406Botulinum toxins for the prevention of migraine in adults.Cochrane Database Syst Rev2018https://conductscience.org/library/papers/29939406PubMed
1819621072Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS Med2009https://conductscience.org/library/papers/19621072PubMed
1935658247
Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization-Observation-Behavior-Intensity-Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing.
Biomed Pharmacother2022https://conductscience.org/library/papers/35658247PubMed
2035631592Translational Value of the Transdermal Administration of Bergamot Essential Oil and of Its Fractions.Pharmaceutics2022https://conductscience.org/library/papers/35631592PubMed

See all 129 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.

PMIDTitleJournalYearIn PapersSource
42935666Procedural interventions for chronic migraine: an umbrella review intervention-specific evidence map.Front Neurol2026https://conductscience.org/library/papers/42935666PubMed
42640284A Three-Point, Low-Dose, Artery-Targeted Botulinum Toxin Treatment for Chronic Migraine: A Randomized, Double-Blind, Contralateral-Controlled Trial.Aesthetic Plast Surg2026https://conductscience.org/library/papers/42640284PubMed
42460013Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy.Front Pharmacol2026https://conductscience.org/library/papers/42460013PubMed
42168840Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond.J Headache Pain2026https://conductscience.org/library/papers/42168840PubMed
41591179Botulinum Toxin Type A for the Prevention of Migraines: An Umbrella Review of Systematic Reviews.Toxins (Basel)2026https://conductscience.org/library/papers/41591179PubMed
41484284A proof-of-concept study on the effectiveness of botulinum toxin on spasticity plus syndrome in multiple sclerosis.Neurol Sci2026https://conductscience.org/library/papers/41484284PubMed
40711166Translational Impact of Genetics and Epigenetics of CGRP System on Chronic Migraine Treatment with Onabotulinumtoxin A and Other Biotech Drugs.Toxins (Basel)2025https://conductscience.org/library/papers/40711166PubMed
40693647Efficacy of Low-Dose BoNT-A Acupoint Injections in Managing Headache, Vertigo, and Allodynia in Vestibular Migraine.J Int Adv Otol2025https://conductscience.org/library/papers/40693647PubMed
40559870Patient Satisfaction with Aesthetic Outcomes Following OnabotulinumtoxinA Treatment for Chronic Migraine: A Cross-Sectional Study.Toxins (Basel)2025https://conductscience.org/library/papers/40559870PubMed
39810518Advances in Migraine Treatment: A Comprehensive Clinical Review.Curr Protein Pept Sci2025https://conductscience.org/library/papers/39810518PubMed
39734637Comprehensive list of preventative migraine headache medications without significant drug-drug interactions.Front Neurol2024https://conductscience.org/library/papers/39734637PubMed
39195765The Potential Therapeutic Effects of Botulinum Neurotoxins on Neoplastic Cells: A Comprehensive Review of In Vitro and In Vivo Studies.Toxins (Basel)2024https://conductscience.org/library/papers/39195765PubMed
38962481The effectiveness and predictors influencing the outcome of onabotulinumtoxinA treatment in chronic migraine: understanding from diverse patient profiles in a single session.Front Neurol2024https://conductscience.org/library/papers/38962481PubMed
38910144Effectiveness and safety of pharmacological prophylaxis for chronic migraine: a systematic review and network meta-analysis.J Neurol2024https://conductscience.org/library/papers/38910144PubMed
38441599Subjective Discomfort during Botulinumtoxin Injections Dependent on Injection Site and Needle Size: A Comparison Between 30G, 33G and 34G Needles.Aesthetic Plast Surg2024https://conductscience.org/library/papers/38441599PubMed
38409723Efficacy and Safety Analysis of Botox Application and Iatrogenic Botulism: Panacea or Peril?Curr Pharm Des2024https://conductscience.org/library/papers/38409723PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37235366

GET https://conductscience.org/api/papers/v1/37235366/references?page=2